Main > A1. CORP. INDEX. M-Mm > Maquet Holding BV & Co. KG. C2 > Maquet CardioVascular/P C2 > 2012. 08.27.2012. AMI>CardioGenic

---

30-day results from the large, randomized, multicenter IABP- SHOCK II ("SHOCK II") clinical trial in patients with acute myocardial infarction (AMI) who were in cardiogenic shock and undergoing early revascularization. The findings showed that use of "intra-aortic balloon counterpulsation (IABC) therapy" was associated with an observed improvement in all-cause mortality at 30 days, but the trial did not meet the pre-specified 12 percent improvement in survival endpoint compared with standard medical therapy.

- Marc Cohen; Mount Sinai



2012. 08.27.2012. AMI>CardioGenic's products
This section has no products